 |
 Video: What is a Stock Split?
|
|
|
| Vera Therapeutics is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Co.'s primary product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, with potential for the treatment of IgA nephropathy. Co. has obtained worldwide, exclusive development and commercial rights for MAU868, a monoclonal antibody to treat reactivated BK virus (BKV) infections. MAU868 is a clinical-stage neutralizing monoclonal antibody that is directed against BKV, a polyoma virus. According to our Vera Therapeutics stock split history records, Vera Therapeutics has had 0 splits. | |
|
Vera Therapeutics (VERA) has 0 splits in our Vera Therapeutics stock split history database.
Looking at the Vera Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Vera Therapeutics shares, starting with a $10,000 purchase of VERA, presented on a split-history-adjusted basis factoring in the complete Vera Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
05/17/2021 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$12.25 |
|
| End price/share: |
$39.65 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
223.67% |
|
| Average Annual Total Return: |
49.00% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$32,364.52 |
|
| Years: |
2.95 |
|
|
|
|
|
